
Dr. Deenadayalan Munirathnam is a Medical Oncologist associated with Apollo Speciality Hospitals, Madurai, with a clinical focus on the diagnosis and medical management of cancer. His listed areas of practice include chemotherapy, immunotherapy, targeted treatment and bone marrow transplantation.
His listed medical qualifications include MBBS, MD and DM in Medical Oncology. He is also described in his professional profile as a European Certified Medical Oncologist (ECMO) and has been recognised with the Dr. V.S. Gold Medal from Madras Medical College.
His clinical interests include systemic cancer treatment through chemotherapy, immunotherapy, targeted therapy and hormonal treatment. His listed specialist field also includes bone marrow transplantation and the management of patients requiring advanced medical oncology care.
Dr. Munirathnam's professional profile identifies his association with Apollo Speciality Hospitals, Madurai, and lists Tamil and English among his consultation languages.
Decades of expertise, proven results, and compassionate care — here is why patients from 50+ countries trust Dr. Deenadayalan Munirathnam for Medical Oncology treatment in India.
Over 20 years of dedicated clinical experience with 5,000+ procedures. One of the most trusted names in Medical Oncology in India.
Dr. Deenadayalan Munirathnam regularly treats patients from Africa, the Middle East, Central Asia, and Europe. Dedicated international patient support team available 24/7.
Practices at an internationally accredited hospital, ensuring patient safety standards that match the best hospitals in the USA and Europe.
World-class treatment at a fraction of USA, UK, or Australian prices. Transparent cost estimates provided before you travel.
Dr. Deenadayalan Munirathnam holds postgraduate qualifications from premier Indian institutions and has advanced fellowship training in DM (Medical Oncology)
Every case is personally reviewed. Treatment plans are tailored, transparent, and discussed in detail before you make any decisions or travel arrangements.
Targeted therapy, immunotherapy, and chemotherapy tailored to molecular profile for all stages.
Hormone therapy, HER2-targeted agents, chemotherapy, and CDK4/6 inhibitors across all subtypes.
Chemotherapy, targeted biologics (bevacizumab, cetuximab), and immunotherapy for GI malignancies.
Platinum-based chemotherapy, EGFR inhibitors, and PD-L1 checkpoint inhibitors.
R-CHOP, R-DHAP, ABVD, and checkpoint inhibitors for all histological subtypes.
Induction chemotherapy, targeted kinase inhibitors, and novel agent combinations for haematological malignancies.
Platinum/taxane-based regimens, PARP inhibitors (BRCA-mutated), and bevacizumab for ovarian and cervical cancers.
Immunotherapy (checkpoint inhibitors), targeted therapy, and hormonal agents for kidney, bladder, and prostate cancers.
Anthracycline-based first-line chemotherapy and trabectedin for advanced sarcomas.
Evidence-based systemic chemotherapy regimens delivered safely with meticulous toxicity management.
Precision oncology using small molecule inhibitors and monoclonal antibodies matched to tumour biology.
PD-1, PD-L1, and CTLA-4 inhibitors harnessing the immune system to fight cancer.
Comprehensive biomarker profiling to match each patient to the most effective treatment.
Endocrine manipulation and DNA-damage repair inhibitors for hormone-receptor-positive and BRCA-mutated cancers.
Send your medical reports and get a personalised treatment plan. The team reviews cases from 50+ countries and responds within 24 hours.
Our team responds within 24 hours
Share your reports and receive a personalised treatment recommendation within 48 hours — at no cost.